Fosfomycin inhibits NF-kappaB activation in U-937 and Jurkat cells.
Fosfomycin exerts anti-inflammatory effects through inhibiting the production of proinflammatory cytokines. Transcription of the genes for these proinflammatory cytokines is regulated by NF-kappaB. We tested the hypothesis that fosfomycin inhibits the activation of NF-kappaB induced by tumor necrosis factor-alpha (TNF-alpha) in human monocytic U-937 cells, and a T cell line (Jurkat). Western blot analysis demonstrated that fosfomycin inhibits NF-kappaB activation in both cells. Flow cytometry revealed that fosfomycin suppresses NF-kappaB activation in both cells in a dose-related manner. These findings are consistent with the idea that fosfomycin suppresses the production of proinflammatory cytokines via inhibition of NF-kappaB activation.
Yoneshima
Yasuto
Y
Department of Pediatrics, Yamaguchi University School of Medicine, 1-1-1 Minamikogushi, Yamaguchi 755-8505, Ube, Japan.
Ichiyama
Takashi
T
Ayukawa
Hiroshi
H
Matsubara
Tomoyo
T
Furukawa
Susumu
S
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D015153:Blotting, Western; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D005578:Fosfomycin / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D019169:Jurkat Cells; D016328:NF-kappa B / Q000235:genetics* / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D020298:U937 Cells
D000900:Anti-Bacterial Agents; D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha; D005578:Fosfomycin